drugset
drugset / Trial / NCT03718299

A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis

NCT03718299 ↗

Phase 4 Completed 55 enrolled Sun Pharmaceutical Industries, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, Week 52 and Week 64, with subjects receiving tildrakizumab injections at Week 0, Week 4, Week 16, Week 28, Week 40, and Week 52. The total study duration will be approximately 64 weeks, excluding a screening period.

Timeline

Start
2019-07-16
Primary completion
2021-11-02
Completion
2021-11-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Tildrakizumab Monoclonal antibody 100 mg —

Indications

psoriasis